Delivery Order SPE2DB25D3404-SPE2DB25FUPMV
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,013.49 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 36.25 MG-145 MG capsules (100-count) under a firm fixed-price contract. The award was made on September 15, 2025, with an ultimate completion date of September 16, 2025, and does not include a set-aside designation. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,935.59 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $2,102.87 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg–195 mg capsules (100 count) on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,826.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RYTARY ER (extended-release carbidopa/levodopa) 36.25 mg-145 mg capsules, 100-count bottles. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 8, 2025. AmerisourceBergen will fulfill this pharmaceutical supply requirement from its corporate office location in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $6,241.31 to AmerisourceBergen Drug Corp for Rytary ER 36.25 mg–145 mg capsules (100-count supply) on June 5, 2025, with completion scheduled for June 6, 2025. This non-set-aside, firm fixed-price delivery order represents pharmaceutical procurement for military healthcare support. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement and holds...
- The Defense Logistics Agency awarded a delivery order valued at $13,844.36 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Rytary ER (carbidopa-levodopa extended-release) 36.25 mg-145 mg capsules in a quantity of 100 units. This is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive set-aside award. The product will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,670.46 to AmerisourceBergen Drug Corp for RYTARY ER 48.75 mg-195 mg capsules (100-count supply) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, to be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,989.57 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count packages). This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive award under DLA's existing supply chain framework. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $44,283.84 to AmerisourceBergen Drug Corp for the supply of RYTARY ER (extended-release carbidopa-levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. The contract is a firm fixed price delivery order with an ultimate completion date of June 9, 2025, and was awarded on June 6, 2025 without any set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.55 to AmerisourceBergen Drug Corp for RYTARY ER 36.25 mg-145 mg capsules (100-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUPMVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,483.62 to AmerisourceBergen Drug Corp for RYTARY ER 23.75 mg-95 mg capsules (100-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitively awarded transaction. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement serving military and veteran healthcare systems. The company supplies a comprehensive range of pharmaceutical products and medical supplies, including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. RYTARY (carbidopa-levodopa) is a neurological treatment used in Parkinson's disease management, reflecting the company's extensive portfolio of specialty medications supporting the Defense Health Agency and other government healthcare systems. This delivery order exemplifies the DLA's pharmaceutical supply chain operations, which leverage prime vendor relationships to ensure reliable access to essential medications for military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.5k | 7/30/25 |